nCage Therapeutics announced today that it had recently completed a collaboration agreement with Nottingham University in the United Kingdom to develop a first-in-class Chagas vaccine. nCage Chief Executive Officer and President of the Management Board, Dr. John Bason, PhD. Noted, “We are extremely pleased to collaborate with a global Chagas Research leader at Nottingham University. Chagas is an unmet need in many countries in Latin America, and an effective vaccine would be a significant step in providing better health outcomes.

View our downloadable document for more information.